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The aim of personalized medicine is to offer a tailored approach to each patient in order to provide the most effective therapy, while
reducing risks and side effects. The use of mineralocorticoid receptor antagonists (MRAs) has demonstrated major benefits in heart failure
with reduced ejection fraction (HFrEF), results with challenging inconsistencies in heart failure with preserved ejection fraction (HFpEF),
and ‘neutral’ preliminary results in acute heart failure. Data derived from landmark trials are generally applied in a ‘one size fits all’ manner
and the development and implementation of more personalized MRA management would offer the potential to improve outcomes and
reduce side effects. However, the personalization of pharmacotherapy regimens remains poorly defined in the cardiovascular field (in light
of current knowledge) and until further trials targeting specific subpopulations have been conducted, MRAs should be provided to the
great majority of HFrEF patients in the absence of contraindication. Spironolactone should be considered for symptomatic HFpEF patients
with elevated natriuretic peptides. In the near future, trials should target HFrEF patients using exclusion criteria sourced from landmark
trials (e.g. severe renal impairment), select more homogeneous HFpEF populations (e.g. with elevated BNP and structural abnormalities on
echocardiography), and determine which patients are likely to benefit from MRAs (e.g. according to prespecified biomarkers).
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Introduction
The aim of personalized medicine is to offer a tailored approach
to each patient in order to provide the most effective therapy,
while reducing risks and side effects, and also avoiding unnecessary
treatments or diagnostic interventions.1,2
The treatment of patients with heart failure with reduced ejec-
tion fraction (HFrEF) has improved in recent decades as a result
of data sourced from several large randomized controlled trials
(RCTs). In contrast, progress has been much less pronounced in
chronic heart failure with preserved ejection fraction (HFpEF) and
in acute heart failure (AHF) syndromes, in which disease-modifying
therapies are urgently needed. For instance, the use of mineralo-
corticoid receptor antagonists (MRAs) has demonstrated major
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.. benefits in HFrEF, results with challenging inconsistencies in HFpEF,
and ‘neutral’ preliminary results in AHF.
Despite these remarkable advances, data derived from land-
mark trials are generally applied in a ‘one size fits all’ manner. The
broad application of a personalized approach to heart failure (HF)
treatment has not become routine. The development and imple-
mentation of more personalized management (e.g. the creation of
multidisciplinary care teams for high-risk HF patients) offers the
potential to improve outcomes,3 but personalization of pharma-
cotherapy regimens remains poorly defined.
Post hoc analyses from the trial datasets provide insights into
disease classification, prognosis and differential treatment effects
of guideline-directed medical therapy, which may provide the basis
for incremental steps towards personalized HF therapy. However,
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Table 1 Main findings of trials of treatment with mineralocorticoid receptor antagonists in heart failure
Variable RALES EMPHASIS EPHESUS TOPCAT
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Population HFrEF HFrEF HFrEF HFpEF
Severe symptoms Mild symptoms Post-MI Symptomatic
Drug (vs. placebo) Spironolactone Eplerenone Eplerenone Spironolactone
Dose ∼25 mg/day ∼50 mg/day ∼50 mg/day 15–45 mg/day
Primary endpoint ACM CO CO CO
HR (95% CI) for TTx 0.70 (0.60–0.82) 0.63 (0.54–0.74) 0.87 (0.79–0.95) 0.89 (0.77–1.04)
ACM, all-cause mortality; CI, confidence interval; CO, composite outcome of death from cardiovascular causes or hospitalization for heart failure in EMPHASIS and TOPCAT
and death from cardiovascular causes or hospitalization for cardiovascular events in EPHESUS; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with
reduced ejection fraction; HR, hazard ratio; MI, myocardial infarction; TTx, treatment.
in view of their retrospective nature, these data are prone to bias
and, in general, should be considered as hypothesis-generating.4
In this review, we aim to analyse which HF subgroups are
likely to experience the greatest benefit of MRA therapy, while
(ideally) experiencing fewer side effects and less treatment with-
drawal. These data may be helpful in supporting the better treat-
ment of patients, in the selection of patient populations in future
MRA trials and in guiding inclusion profiles in future platform
trials.5
Methodological background:
assessing differential impacts
according to subgroups
The differential impacts of MRA treatment can be assessed by interac-
tion analysis using MRA trial databases. The term ‘interaction’ in the
field of biostatistics refers to the impact of a given variable on the effect
of another variable. In the present context, such interaction analyses
were those that assessed whether MRA treatment has a differential
impact in specific subgroups of patients.6 In addition, we also assessed
the absolute risk reduction (ARR) on the primary outcome of each
major MRA trial in order to present treatment effects on an abso-
lute scale rather than a relative one, as the former can provide more
clinically useful information.7,8
Heart failure with reduced
ejection fraction
Therapy with MRAs for HFrEF has been evaluated in three
large RCTs: (i) the Randomized Aldactone Evaluation Study
(RALES);9 (ii) the Eplerenone in Patients with Systolic Heart
Failure and Mild Symptoms Study (EMPHASIS);10 and (iii) the
Eplerenone Post-Myocardial Infarction Heart Failure Efficacy
and Survival Study (EPHESUS)11 (discussed later in the present
manuscript; see AHF section). These trials showed that MRAs,
in addition to standard HF therapy, substantially reduced the
risk for both morbidity and mortality among patients with
severe, mild and post-myocardial infarction (MI) HFrEF. However,
is this true for all HFrEF patients included in these landmark
trials? .
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. Heart failure with reduced ejection
fraction and severe symptoms
In the RALES trial, 1663 patients with HF and severe symptoms and
a left ventricular ejection fraction (LVEF) of≤35%were randomized
to spironolactone or placebo. There was a 30% reduction in
mortality in the spironolactone group [hazard ratio (HR) 0.70, 95%
confidence interval (CI) 0.60–0.82; P < 0.001]. The main findings
of this trial are summarized in Table 1.
In an absolute scale derived from Kaplan–Meier curves, the ARR
of all-cause death at 2 years was ≈7%, which provides a number
needed to treat (NNT) of ≈14 patients at 2 years to avoid one
death (Figure 1).
Subgroup efficacy
The beneficial effect of spironolactone was present across vari-
ous subpopulations [i.e. the reduction in the risk for death among
patients in the spironolactone group was similar; P-value for
interaction: non-significant (NS)] in analyses of all prespecified sub-
groups (Table 2). This subgroup consistency increases the internal
validity and the overall robustness of the results.
Additional prespecified and exploratory post hoc analyses were
performed in order to provide further insight regarding treatment
efficacy, safety and underlying mechanisms (Table 2).
Renal function and serum potassium
A post hoc analysis of the RALES trial provided further insight
into the influence of baseline and worsening renal function [WRF;
defined as a ≥30% reduction in estimated glomerular filtration
rate (eGFR) from baseline to week 12 of follow-up] on the effi-
cacy of spironolactone.12 Patients with a baseline eGFR of <60
mL/min/1.73 m2 exhibited reductions in all-cause death similar
to those in patients with a baseline eGFR of ≥60 mL/min/1.73
m2. Moreover, WRF was more frequent in the spironolactone
group, yet these patients did not have higher all-cause mortality
rates, whereas in the placebo group, patients with WRF demon-
strated increased mortality compared with those without WRF
(HR 1.1, 95% CI 0.8–1.5 in the spironolactone group; HR 1.9,
95% CI 1.3–2.6 in the placebo group; P = 0.009 for interaction).
An additional analysis showed that patients who experienced mild
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Figure 1 Comparison of absolute risk reduction (ARR) and number needed to treat (NNT) to benefit between trials of mineralocorticoid
receptor antagonists. The primary outcome of each trial was used in the present interpretation. NS, non-significant.
hyperkalaemia (up to a potassium level of 5.5 mmol/L) derived
benefit from spironolactone treatment, whereas patients random-
ized to placebo had increased death rates.13 These data sug-
gest that despite lower eGFR and/or the occurrence of WRF or
hyperkalaemia (up to a potassium level of 5.5 mmol/L), an effort
should be made to maintain MRA therapy (with adequate dose
adjustment) as it is associated with improved outcomes in these
patients.
Race
Another post hoc analysis of RALES investigated whether race
influenced the effect of spironolactone.14 Patients were divided
into African Americans (AAs) (n = 120) and non-AAs (n = 1543).
After adjustment, there were no significant differences between
these subgroups in the primary outcome of all-cause death (HR
0.69, 95% CI 0.59–0.81 in non-AAs; HR 0.91, 95% CI 0.52–1.60
in AAs; P-value for interaction: NS). However, spironolactone
reduced the combined endpoint of death or hospitalization for HF
in non-AAs (HR 0.63, 95% CI 0.55–0.73) but not in AAs (HR 1.07,
95% CI 0.67–1.71; P = 0.032), who also did not experience the
expected spironolactone side effects, such as mild hyperkalaemia
(Table 2). These data should be interpreted very cautiously. The AA
subgroup is very small and likely to have low power and insufficient
precision to evaluate significant differences between subgroups.
Moreover, these data represent point estimates and do not account ..
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.. for therapeutic adherence. Other potential explanations for these
differences have been studied. For example, the aldosterone syn-
thase promoter 344-C allele is linked to higher aldosterone levels
and is associated with poorer event-free survival in HF.15 African
Americans without this allele (the majority) are likely to have a
lower response to MRAs.16 Other genetic factors have also been
identified and associated with renal function decline, which may
have an impact on outcomes, MRA indication and response.17
Summary of subgroup analysis
Overall, the efficacy of spironolactone was consistent across all
the studied subgroups. Despite the finding of possibly less efficacy
in AAs, these observations are derived from a retrospective
point analysis with unbalanced groups and do not account for
therapeutic compliance. Hence, the benefits of spironolactone can
be generalized to all patients with HF and severe symptoms unless
formal contraindicated.
Predictors of efficacy
A prespecified analysis of the RALES trial assessed samples of
261 patients to determine their fibrotic status through measure-
ments of serum procollagen type I carboxy-terminal peptide,
procollagen type I amino-terminal peptide, and procollagen type
III amino-terminal peptide (PIIINP) levels at baseline and at 6
months.18 Elevated baseline levels of PIIINP were associated
© 2017 The Authors
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Table 2 Differences between patient subgroups in treatment effect in major trials of treatment with
mineralocorticoid receptor antagonists in heart failure
Variable RALES EMPHASIS EPHESUS TOPCAT
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age (above vs. below median) NS NS 0.93 (0.82–1.05) —
HR (95% CI), P-value for interaction 0.78 (0.70–0.92)
P = 0.08
Sex (male vs. female) NS NS 0.82 (0.72–0.93) —
HR (95% CI), P-value for interaction 0.95 (0.71–1.11)
P = 0.08
Race (non-AA vs. AA) 0.6 (0.6–0.7) — — —
HR (95% CI), P-value for interaction 1.1 (0.7–1.7)
P = 0.03
LVEF (above vs. below median) NS NS 0.98 (0.82–1.15) —
HR (95% CI), P-value for interaction 0.81 (0.71–0.90)
P = 0.07
Pulse pressure (above vs. below median) — NS 0.79 (0.70–0.90) —
HR (95% CI), P-value for interaction 0.93 (0.81–1.08)
P = 0.08
Waist circumference (≥102 cm in — 0.48 (0.37–0.63) — —
males/≥ 88 cm in females vs. <102/88 cm) 0.77 (0.61–0.98)
HR (95% CI), P-value for interaction P = 0.01
Atrial fibrillation (yes vs. no) — NS — —
Diabetes mellitus (yes vs. no) — 0.6 (0.5–0.8) NS —
HR (95% CI), P-value for interaction 0.8 (0.6–0.9)
P = 0.10
Hypertension (yes vs. no) — NS NS —
QRS interval (≤130 ms vs. >130 ms) NS — —
Potassium levels (above vs. below median) NS — 0.95 (0.85–1.10) —
HR (95% CI), P-value for interaction 0.77 (0.70–0.90)
P = 0.02
Creatinine or eGFR (above vs. below
median)
NS NS NS —
Collagen synthesis markers (above vs. below
median)
0.4 (0.3–0.8)
1.1 (0.7–1.9)
— —
HR (95% CI), P-value for interaction P < 0.05
Enrolment stratum (NPs vs. hospitalization) NS — 0.7 (0.5–0.9)
HR (95% CI), P-value for interaction 1.0 (0.8–1.92)
P = 0.01
Geographical region (west vs. east) — NS — 0.7 (0.6–1.0)
HR (95% CI), P-value for interaction 1.3 (0.9–1.9)
P = 0.01
Digitalis use (yes vs. no) NS — — —
ACEi/ARBs (yes vs. no) NS NS NS —
Beta-blockers (yes vs. no) NS NS — —
ACEi + ARBs + beta-blockers (yes vs. no)
HR (95% CI), P-value for interaction
0.9 (0.3–2.2)
0.7 (0.6–0.9)
P = 0.07
NS —
AAs, African Americans; ACEi, angiotensin-converting enzyme inhibitor; ARBs, angiotensin receptor blockers; CI, confidence interval; eGFR, estimated glomerular filtration
rate; HR, hazard ratio; LVEF, left ventricular ejection fraction; NPs, natriuretic peptides; NS, non-significant.
The test for interaction was considered statistically significant at a P-value of ≤0.1 for the primary outcome of each trial.21
with an increased risk for death. At 6 months, markers
decreased in the spironolactone group but remained unchanged
in the placebo group. The spironolactone effect on outcome
was significant only in patients with above-median baseline
levels of markers. For example, the HR values for death among
patients receiving spironolactone were 0.44 (95% CI 0.26–0.75; .
..
..
..
..
..
..
..
. P= 0.002) in the subgroup of patients with PIIINP levels above the
median and 1.11 (95% CI 0.66–1.88; P = 0.70) in the subgroup
with PIIINP levels below the median (P < 0.05 for interaction)
(Table 2). These results show that serum levels of cardiac collagen
synthesis were significantly associated with poor outcome, but
could be decreased by spironolactone. Moreover, the morbidity
© 2017 The Authors
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and mortality-related benefits to be derived from spironolac-
tone are greater in patients with the highest (above the median)
levels of these markers. These results suggest that limitation of
the excessive extracellular matrix turnover may represent one
of the various mechanisms contributing to the beneficial effect
of spironolactone.
These findings are interesting because they derive from a pre-
specified randomized analysis and clearly show different response
patterns. Hence, these data may help to identify a subgroup of
potential ‘super-responders’ represented by patients with high
collagen synthesis markers, in whom an early and well-titrated
treatment with spironolactone could provide substantial prog-
nostic benefit. However, spironolactone was not likely to be
deleterious in patients with lower collagen synthesis marker
levels and thus, until further prospective randomized evidence
is available, spironolactone should still be used in this (lower
collagen synthesis) HFrEF subgroup of patients. These find-
ings may also suggest potential for biomarker-guided therapy,
although this would require prospective validation prior to broad
application.19
Safety
There were no significant differences between the spironolactone
and placebo treatment groups in serum sodium concentration,
blood pressure or heart rate during the RALES study. How-
ever, the median creatinine concentration in the spironolactone
group increased by approximately 0.05–0.10 mg/dL and median
potassium concentration increased by 0.30 mmol/L during the
first year after enrolment, whereas in the placebo group, no
changes were detected (between-group difference, P < 0.001).
Of note, the increases in potassium and creatinine in the spirono-
lactone group were not associated with increased mortality
(as explained above). Overall, spironolactone was safe and well
tolerated in the context of trial measurements of potassium
and creatinine. Importantly, recent real-world data highlight that
these laboratory evaluations are not consistently performed in
routine practice, and the question of whether ‘regular’ potassium
and creatinine measurements in the context of MRA treat-
ment are associated with improved outcomes needs further
evaluation.20
Heart failure with reduced ejection
fraction and mild symptoms
In the EMPHASIS trial, 2737 patients with HF, LVEF of ≤35% and
mild symptoms were randomly assigned to receive eplerenone
(up to 50 mg/day) or placebo. The primary outcome was a
composite of death from cardiovascular causes or hospitalization
for HF.10 There was a 37% reduction in the primary outcome in
the eplerenone group (HR 0.63, 95% CI 0.54–0.74; P < 0.001)
(Table 1).
In an absolute scale derived from the Kaplan–Meier curves, the
ARR of the primary composite outcome at 2 years was ≈8%, which
provides an NNT of ≈13 patients at 2 years to avoid one event
(Figure 1). Considering all-cause death as the outcome (the primary ..
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.. outcome used in RALES), the ARR was ≈4%, providing an NNT of
≈25 patients at 2 years to avoid one death.
These results were also impressive and even more so if
we consider that the great majority of patients were also
receiving ACE inhibitor (ACEi)/angiotensin receptor blocker
(ARB) and beta-blocker background therapy, which was not
the case in RALES, in which only ≈10% of patients were on
beta-blockers.
Subgroup efficacy
The beneficial effect of eplerenone was consistent across the
various subpopulations studied in that the reduction in the risk
for death among patients in the eplerenone group was similar (P
≥ 0.05 for interaction) in analyses of all prespecified subgroups
(Table 2). However, the test for interaction is statistically weak
and some authorities argue that a larger P-value, such as ≤0.1,
should be considered as possibly indicative of a true interaction.21
In this regard, patients with diabetes were likely to experience
greater benefit from eplerenone than patients without diabetes
(HR 0.6, 95% CI 0.5–0.8 vs. HR 0.8, 95% CI 0.6–0.9; P = 0.10
for interaction) and patients receiving an ACEi plus ARB plus
beta-blocker were less likely to experience the beneficial effects of
eplerenone (HR 0.9, 95% CI 0.3–2.2 vs. HR 0.7, 95% CI 0.6–0.9;
P= 0.07 for interaction) (Table 2). Despite these weak interactions,
efficacy was likely to be maintained (HR reduction) across these
subgroups, which supports the similar use of MRAs in these
subpopulations. Additional prespecified and post hoc analyses were
performed in order to generate further insight into treatment
efficacy, safety and underlying mechanisms.
High-risk subgroups
A prespecified analysis of the EMPHASIS trial sought to investigate
the safety and efficacy of eplerenone in patients at high risk for
hyperkalaemia and/or WRF. These prespecified high-risk patients
fulfilled at least one of the following criteria: age ≥75 years; a diag-
nosis of diabetes; an eGFR of <60 mL/min/1.73 m2, and systolic
blood pressure of <123 mmHg (median). The studied endpoints
were hyperkalaemia leading to study drug discontinuation or
hospitalization, hospitalization for WRF, and the primary outcome
of hospitalization for HF or cardiovascular death. Patients treated
with eplerenone showed an effective reduction in the primary
outcome in all high-risk subgroups.22,23 The beneficial effect of
eplerenone was also observed regardless of the presence of atrial
fibrillation at baseline.24 Other post hoc analyses also documented
the maintenance of a survival benefit of eplerenone in patients
with WRF and/or hyperkalaemia during follow-up,25 in patients
with abnormal QRS morphology and duration,26 and in patients
taking aspirin.27
These results are consistent with those of RALES and support
the use of MRAs in high-risk subgroups, which also represent
the populations likely to most benefit from disease-modifying
therapies.
© 2017 The Authors
European Journal of Heart Failure © 2017 European Society of Cardiology
MRA therapy in heart failure patients 979
Waist circumference
Based on experimental data suggesting a better MRA response in
the presence of abdominal adiposity,28 HFrEF patients included in
the EMPHASIS trial were divided according to their waist circum-
ference (WC). This post hoc analysis suggested that patients with
‘increased’ WC derived greater benefits from MRA eplerenone
(HR 0.48, 95% CI 0.37–0.63 for subjects with a WC of ≥102 cm
in males or ≥88 cm in females vs. HR 0.77, 95% CI 0.61–0.98
for subjects with a WC of <102 cm in males or <88 cm in
females; P= 0.01 for interaction) compared with patients with
a ‘normal/near normal’ WC with a similar safety profile.29 This
observation was not significant in analyses of the benefit derived
from eplerenone according to the presence of obesity defined by
body mass index (BMI), which suggests that abdominal adipos-
ity plays a pivotal role in modulating MRA response.28 However,
these data represent post hoc findings and should be interpreted
very cautiously. For example, in patients with a ‘normal/near nor-
mal’ WC, a beneficial effect of eplerenone for which the 95%
CIs overlapped those applying to patients with an ‘increased’ WC
was also observed. Not until further replication has been car-
ried out and prospective confirmation obtained can MRA ther-
apy be tailored according to WC. However, these data may raise
the hypothesis that patients with abdominal obesity may respond
better to MRAs. Moreover, future research should try to assess
the mechanisms inherent in the ‘obesity paradox’ findings in HF,
which has been observed with regard to BMI (and not WC, details
of which are much less available in datasets).30,31 Nonetheless,
the question of whether there is a different pattern of response
to renin–angiotensin–aldosterone inhibitors in obese patients
remains to be answered.
Safety
Although mild to moderate hyperkalaemia occurred more fre-
quently in patients treated with eplerenone [serum potassium lev-
els of >5.5 mmol/L occurred in 11.8% of patients in the eplerenone
group and 7.2% of those in the placebo group (P < 0.001)], rates
of severe hyperkalaemia did not differ between the treatment and
placebo groups [serum potassium levels of >6.0 mmol/L occurred
in 2.5% of patients in the eplerenone group and 1.9% of those in the
placebo group (P = 0.29)].10 Changes in serum creatinine did not
differ significantly between the groups. The safety profile was main-
tained across high-risk subgroups, with no differences with respect
to severe hyperkalaemia or study drug discontinuation.22
Overall interpretation of subgroup
analysis in heart failure with reduced
ejection fraction
The use of MRAs (either spironolactone or eplerenone) is effective
and safe in HFrEF. Use of these therapies should be generalized to
this population unless contraindicated (according to the current
guidelines).32,33 A prespecified analysis of the RALES trial identified
patients with higher levels of cardiac collagen synthesis markers
as potential ‘super-responders’ to MRA therapy.18 However, this ..
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.. approach is not currently recommended to identify HFrEF patients
who will respond to therapy (as these data are derived from a small
subpopulation of the RALES trial), and therefore these data require
additional prospective and well powered validation.
One suggestion is that future HFrEF trials prespecify mea-
surements of collagen markers in all patients included at base-
line and then measure levels of these biomarkers regularly within
the trial (e.g. every 6–9 months) and plot the resultant data
against events (e.g. hospitalizations, diuretic increase, WRF, hyper-
kalaemia). The time-points at which the data are examined should
also be prespecified (e.g. 50% and 75% of the total enrolment).
This would allow the evaluation of potential responders (e.g.
those with elevated collagen markers that decrease over time) vs.
non-responders (or those with low event risk) who experience
only the adverse effects of the treatment (e.g. those with persis-
tently low collagen markers). In this context, the trial may require
some adaptation and a recalculation of sample size to include only
patients with elevated collagen markers in order to support a
robust conclusion about the effects of treatment in these patients
while limiting the chances of type I error. An early termination of
the trial could also be decided in the face of an ‘unequivocal’ benefit
in one subgroup.34 Clearly, this might change the face of cardiovas-
cular trials and provide compelling indications for the use of MRAs
above and beyond usual care.
Heart failure with preserved
ejection fraction
The TOPCAT trial enrolled 3445 patients with symptoms
attributable to HF and an LVEF of ≥45% to receive either
spironolactone (15–45 mg/day) or placebo. The primary outcome
was a composite of cardiovascular mortality, aborted cardiac
arrest and HF hospitalization.35 Overall, spironolactone did not
reduce the primary outcome in comparison with placebo (HR
0.89, 95% CI 0.77–1.04; P = 0.14) (Table 1). Of the components
of the primary outcome, only hospitalization for HF occurred at a
significantly lower incidence in the spironolactone group than in
the placebo group (HR 0.83, 95% CI 0.69–0.99; P = 0.04).
Subgroup efficacy
Given differences in outcomes by region and HF entry criteria,
the data derived from the TOPCAT trial are complex and several
additional post hoc analyses have been performed to explore these
findings (Table 2).
Geographical differences
The TOPCAT trial showed marked geographical differences
regarding treatment effect. Patients from ‘the Americas’ (North
and South America) showed a marked response to treatment,
whereas patients from Eastern Europe (Russia and Georgia) did
not.36–38 The HRs for the primary outcome of cardiovascular
death or HF hospitalization were 0.82 (95% CI 0.69–0.98; P =
0.026) for subjects in the Americas and 1.10 (95% CI 0.79–1.51;
P = 0.58) for subjects in Eastern Europe (interaction by treatment
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region, P = 0.12). Although the P-value for interaction by treatment
region was not <0.05 for the primary outcome, it should be noted
that the test for interaction is statistically weak, and some authori-
ties argue that a larger P-value (e.g. of ≤0.1) should be considered
as potentially indicative of a significant interaction.21 Moreover,
HRs for cardiovascular mortality were 0.74 (95% CI 0.57–0.97)
in the Americas and 1.31 (95% CI 0.91–1.90) in Eastern Europe
(P = 0.01 for interaction). Although cardiovascular death was a
component of the primary outcome (but a prespecified analysis),
here the P-value for interaction is indisputably significant and is
unlikely to represent a chance finding.39 Subgroup analyses (that
include geographical differences) should be interpreted cautiously
and very often represent a consequence of randomness and/or
multiple testing.40 However, the geographical differences in TOP-
CAT are unlikely to be a product of chance as there is strong
‘biological’ plausibility for the treatment differences observed. In
TOPCAT, huge discrepancies in baseline characteristics and event
rate were observed between patients randomized from Eastern
Europe and those enrolled from the Americas, whereby the latter
showed an approximately four-fold higher event rate. In fact, rates
of events in patients from Eastern Europe were similar to those
in age-matched individuals from the general population36 and
spironolactone metabolites were undetectable in these patients,
which suggests that the great majority were not taking the study
drug.41 We may assume that patients’ baseline characteristics,
discrepancies in inclusion criteria and treatment adherence played
major roles in the difference in treatment effect.38 However, the
study was not stratified by region and did not feature an adaptive
design that would have allowed for the adjusting of randomization
regions along the trial (i.e. ‘the Americas’ would have been a
‘winner’) and, unfortunately, in international recommendations
these data are treated as merely ‘post hoc’ and current guidelines
provide no specific recommendations regarding spironolactone in
HFpEF.32,33 However, based on the aforementioned justifications,
it is our opinion that the weight of the available evidence favours
spironolactone use, and that this treatment is useful and should be
considered for the purposes of reducing morbidity and mortality
in symptomatic HFpEF, the diagnosis of which can be assessed with
more granularity using natriuretic peptides (NPs; as demonstrated
below) (Table 2 and Figure 1).
Stratification: BNP stratum vs. hospitalization stratum
Importantly, the TOPCAT trial was stratified according to the entry
criteria for HF. Patients were randomized according to BNP or
HF hospitalization strata. Those in the BNP stratum (NT-proBNP
>360 pg/mL for inclusion) showed a positive response to spirono-
lactone treatment and a major reduction in primary outcome event
rate, whereas those in the hospitalization stratum did not (HR
0.65, 95% CI 0.49–0.87 in the BNP stratum vs. HR 1.01, 95% CI
0.84–1.21 in the hospitalization stratum; P = 0.01 for interaction).
From a methodological perspective, interactions between pre-
specified randomized strata have a higher value than those derived
from post hoc subgroups. In stratified trials, such as TOPCAT, ran-
domization is performed within each stratum. As a consequence,
the results derived within a given stratum are ‘true’ randomized ..
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.. evidence. Despite concerns that these data may be limited as a
result of multiplicity of testing and type I error, we would like to
propose that spironolactone is beneficial in HFpEF patients (and
has an acceptable safety profile) with elevated NPs42 (Table 2).
Cardiac structure and function
A subanalysis of the TOPCAT trial43 identified echocardio-
graphic variables with prognostic relevance. In particular, left
ventricular (LV) hypertrophy, elevated LV filling pressures and
higher pulmonary artery pressure assessed by tricuspid regurgita-
tion velocity were independently associated with the occurrence
of the primary outcome. Additionally, impaired LV systolic function
assessed by longitudinal strain [LS (absolute LS value: <15.8%)]
was identified as the strongest echocardiographic predictor of
cardiovascular outcomes in TOPCAT. Interestingly, an exploratory
analysis in a subset of 131 patients with follow-up LS assessed
after 12–18 months of trial enrolment demonstrated a significant
improvement (after adjustment for randomization strata and
clinical characteristics) in LS associated with spironolactone in
patients enrolled in ‘the Americas’ (but not in those from Russia
or Georgia).44 Despite potential LS improvement in patients
randomized to spironolactone, this treatment was not associated
with significant differences in measures of LV mass or dimensions
in the 239 patients with echocardiographic follow-up at 12–18
months after randomization.45 A meta-analysis of MRA trials in
HFpEF found a potential association with diastolic improvement
in patients treated with MRAs as assessed by E/E′, deceleration
time and E/A ratio, and, in addition, cardiac collagen markers were
significantly reduced with MRA therapy.46,47
The LVEF spectrum in terms of prognosis and treatment effect
was also analysed in TOPCAT.48 The incidence of the primary
endpoint and cardiovascular death was highest in patients at the
lower end of the ‘preserved’ LVEF spectrum and spironolactone
was likely to provide more benefit to patients with LVEF of 45–60%
(P = 0.046 for interaction).
Despite the limitations inherent in post hoc analysis, these
data suggest that patients with HFpEF but with lower EF and
with impaired contractility are likely to derive more benefit from
spironolactone treatment.
Safety
Overall, treatment with spironolactone in TOPCAT was safe.
Although the treatment was associated with increased serum cre-
atinine levels and a doubling of the rate of mild hyperkalaemia,
there were no significant differences in incidences of severe hyper-
kalaemia or severe renal dysfunction between the spironolactone
and placebo groups.35
Overall interpretation of subgroup
analysis from heart failure with
preserved ejection fraction trials with
mineralocorticoid receptor antagonists
Patients with HFpEF and elevated NPs are likely to benefit from
spironolactone treatment because this effect was tested in a truly
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randomized fashion (within the BNP stratum) and the drug is well
tolerated if adequately monitored. Patients with the characteristics
of those enrolled from ‘the Americas’ in the TOPCAT trial are also
likely to benefit from spironolactone treatment. Patients at the
lower end of LVEF (45–60%) are also more likely to experience
positive effects from spironolactone treatment.
Acute heart failure
Data regarding AHF are scarce and largely are not based on
randomized evidence. The EPHESUS trial,11 which included a very
particular subtype of patients with AHF (≈90% of the patients
presented with signs and symptoms of AHF) comprising those with
acute MI and LVEF of <40%, represents an exception to this, and
hence EPHESUS data cannot be generalized to other populations.
In the EPHESUS trial, the endpoint of death from cardiovascular
causes or hospitalization for cardiovascular events was reduced by
13% in the eplerenone group (HR 0.87, 95% CI 0.79–0.95; P =
0.002) (Table 1).
In an absolute scale derived from Kaplan–Meier curves, the ARR
of the primary composite outcome at 2 years was ≈4%, which
provides an NNT of ≈25 patients at 2 years to avoid one event
(Figure 1).
Subgroup efficacy
The EPHESUS trial clearly showed that eplerenone is effective in
acute MI patients with AHF and LVEF of <40% in comparison with
placebo (HR 0.87, 95% CI 0.79–0.95; P = 0.002 for the primary
outcome of death from cardiovascular causes or hospitalization
for cardiovascular events)49 (Table 2). A subanalysis of EPHESUS
data showed that patients who were randomized to eplerenone
or placebo earlier after acute MI (3–7 days) vs. those who were
randomized later (8–14 days) experienced a greater benefit from
eplerenone treatment [adjusted HR for cardiovascular hospitaliza-
tion and/or cardiovascular mortality 0.78 (95% CI 0.67–0.90; P =
0.001) in early initiation and 0.94 (95% CI 0.93–1.06; P = 0.32)
in late initiation (P = 0.03 for interaction)].50 Moreover, data from
the EMPHASIS trial also suggest that eplerenone improves survival
and prevents readmission in patients in whom the drug is initiated
soon after hospital discharge (<42 days).51 These data support the
claim that the acute setting represents a good context in which to
initiate MRAs.
In acutely decompensated heart failure (ADHF), a small (∼100
patients), single-centre, open-label, non-randomized study sug-
gested that high-dose spironolactone (∼100 mg/day) when initiated
in the first 24 h of hospitalization is associated with a faster diuretic
response and increased spot urine sodium excretion.52–54
The ATHENA-HF (Aldosterone Targeted Neurohormonal
Combined with Natriuresis Therapy–Heart Failure) trial55 was a
double-blind, placebo-controlled trial, in which 360 patients were
randomized to ‘usual care’ vs. ‘usual care’ plus 100 mg/day of
spironolactone for 72 h within the hospital stay. The hypothesis
that treatment with spironolactone would lead to greater reduc-
tions in NT-proBNP levels at 96 h was not met and the findings
of the ATHENA-HF trial were ‘neutral’ [change in logNT-proBNP ..
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.. from baseline to 96 h: −0.49 (95% CI −0.98 to −0.14) in the
‘usual care’ group vs. −0.55 (95% CI −0.92 to −0.18) in the
spironolactone group (P = 0.57)]. Other prespecified endpoints
of dyspnoea relief, clinical congestion, net urine output, weight
loss and clinical events also did not differ between the groups.
Nonetheless, spironolactone treatment was found to be safe
and not associated with higher rates of hyperkalaemia (K+ >5.5
mEq/L) or WRF (Butler J., unpublished data). However, patients
included in the ATHENA-HF trial were relatively young (mean
age: 65 years), were clinically stable and did not have major renal
impairment (mean eGFR: 57 mL/min/1.73m2). Even more striking
were the low mortality rates at 30 days, which amounted to 3.9%
(n = 7 deaths) in the placebo group and 2.7% (n = 5 deaths) in
the spironolactone group (P = 0.50), supporting the ‘low risk’
profile of this ADHF population. It is, therefore, unlikely that
these patients were at risk of ‘diuretic resistance’ or offered chal-
lenges for effective decongestion or for the initiation of life-saving
therapies. In addition, more than 25% of patients in the placebo
group had already received baseline spironolactone treatment and
continued it during their hospital stay. In this context, the results of
the ATHENA-HF trial are as expected. Moreover, spironolactone
has an extensive metabolism and slow onset of action (which
may take >24 h), and therefore is not an appropriate drug in the
acute setting.56 A more interesting approach would involve the
evaluation of i.v. potassium canrenoate in patients with (or prone
to) diuretic resistance.57
Spironolactone shows promising results in AHF after an acute
MI, but did not demonstrate beneficial effects in patients with
ADHF without MI. However, as noted above, the ATHENA-HF
trial was subject to several limitations and the efficacy and safety
of aldosterone antagonists in ADHF should be further explored.
Safety
In AHF, MRAs were well tolerated overall. In the EPHESUS
trial, a non-clinically relevant increase in creatinine levels was
observed in the eplerenone group (0.06 mg/dL vs. 0.02 mg/dL; P
< 0.001). Severe hyperkalaemia (serum potassium concentration
≥6.0 mmol/L) occurred in 5.5% of patients in the eplerenone group
vs. 3.9% of subjects in the placebo group (P = 0.002), and one
death attributed to hyperkalaemia occurred in the placebo group.
The incidence of hyperkalaemia was higher in patients with renal
dysfunction at baseline (eGFR <50 mL/min/1.73 m2).11
Overall interpretation of subgroup
analysis from acute heart failure trials
with mineralocorticoid receptor
antagonists
In patients presenting with acute MI plus AHF and systolic dysfunc-
tion, eplerenone is effective and safe. Its use should be generalized
to the population that meets the EPHESUS criteria. In ADHF, the
results did not suggest benefit; however, other ‘higher-risk’ pop-
ulations and other aldosterone antagonist formulations (with i.v.
administration possibilities) should be tested.
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Table 3 Clinical and research implications of subgroup analysis in trials of angiotensin receptor blockers (ARBs) and
mineralocorticoid receptor antagonists (MRAs) in heart failure
Clinical implications Research implications
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
In heart failure with reduced ejection fraction
Administer MRAs ideally to all patients (unless contraindicated) Include higher-risk subgroups (e.g. severe renal dysfunction)
Treat more patients (validate potassium binders/novel MRAs) Test novel MRAs in populations excluded from previous trials
Test the management of MRA-induced hyperkalaemia with novel potassium
binders in a randomized fashion
Evaluate prospectively the role of biomarkers (e.g. collagen markers) for a
‘personalized approach’
In heart failure with preserved ejection fraction
Provide MRAs to symptomatic patients with elevated NPs Test MRAs in more homogeneous populations (e.g. elevated NPs/structural
abnormalities on echocardiography)
Evaluate prospectively the role of biomarkers (e.g. collagen markers) for a
‘personalized approach’
In acute heart failure
Initiate early administration of MRAs Test higher-risk populations and use aldosterone antagonists in i.v. formulations
Use MRAs for congestion improvement?
In populations ‘at risk’
Treat risk factors according to current recommendations Evaluate prospectively the role of biomarkers (e.g. collagen markers) for a
‘personalized approach’
NPs, natriuretic peptides.
Clinical implications
Heart failure with reduced ejection
fraction
In HFrEF there is at present insufficient evidence to change cur-
rent guidelines towards a more personalized approach.32,33 This
is a high-risk population in which all measures that increase sur-
vival, reduce hospitalization and improve quality of life should be
applied. Given the safety and great efficacy of MRAs in this setting,
there is little reason (in light of current knowledge) to sub-select
HFrEF patients. In contrast, more patients can benefit from MRA
treatment as many patients are still undertreated.58
The advent of potassium-binding therapies may potentially reas-
sure clinicians about prescribing MRAs to subgroups of patients
at high risk for hyperkalaemia.59–62 However, without adequate
prospective evaluation that these potassium binders may actually
help to titrate MRA therapy, reduce side effects and improve out-
comes, the use of these agents cannot be routinely advocated.
Hence, the lack of such evaluation may increase concerns related
to risk for hyperkalaemia associated with the use of MRAs.
Additionally, prospective high-quality evidence should focus on
subgroup selection based on patterns of response and side effects
(Table 3).
Heart failure with preserved ejection
fraction
In the immediate clinical setting, current data suggest that spirono-
lactone could be provided to symptomatic HFpEF patients (for .
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. whom no therapy is currently available) with elevated NPs36,42
(Table 3).
Acute heart failure
All patients with AHF and systolic dysfunction in the context
of acute MI should be treated with MRAs unless their use is
contraindicated. Given their consistent efficacy and safety in this
setting, there is no place for treatment selection based on sub-
groups.
In patients with ADHF, MRA use did not point towards a benefi-
cial effect. However, other drug formulations (e.g. i.v. canrenoate)
and higher-risk populations should be targeted (Table 3).
Research implications
Implications for future research are of the utmost importance in
the provision of high-quality evidence in RCTs.
Heart failure with reduced ejection
fraction (including post-myocardial
infarction)
Heart failure with reduced EF is a high-risk condition in which
event rates are elevated (high event incidence) and patients are
prone to competing risks imposed by factors such as ageing.63 The
use of MRAs effectively reduces those events without increasing
life-threatening adverse effects. The NNT to benefit on an absolute
scale is very low (NNT: <15 at 2 years) and hence MRA treatment
in HFrEF should be inclusive rather than exclusive.64 To this
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Figure 2 Hazard ratio (HR) for mineralocorticoid receptor antagonist (MRA) treatment according to a population’s baseline risk. Estimation
of a population’s risk is based on event rates in the placebo groups of the respective trials. BNP, brain natriuretic peptide.
purpose, treatment effect and safety in high-risk subgroups (e.g.
patients with severe renal dysfunction) can be improved in order
to increase the pool of patients to be treated (e.g. with the use
of novel agents such as finerenone and/or the use of potassium
binders) (Table 3 and Figure 2).
Given the demonstrated reduction in event rates, and the
reproducibility of results, and internal and external validity, it would
be unethical to perform another trial of treatment with MRAs
vs. placebo in HFrEF. Hence, a novel trial in this setting might
compare the new MRA vs. spironolactone or eplerenone in order
to demonstrate the superiority of the new treatment or, at least,
its non-inferiority and improved safety profile. However, the advent
of an adaptive MRA trial may help to determine which patients
will derive more benefit from the novel treatment and the findings
outlined can help to select this patient population while the trial is
ongoing.34,65
Heart failure with preserved ejection
fraction
Patients with symptomatic HFpEF and elevated NPs are subject to
levels of risk similar to those of their HFrEF counterparts. There-
fore, future trials should target a more homogeneous population,38
comprising, for example, symptomatic patients with elevated NPs
plus structural abnormalities on echocardiography (LVEF 45–60%
and/or systolic dysfunction as assessed by LS) as this population is
more prone to benefit from MRA therapy (Table 3 and Figure 2). In
other words, the target population should have the disease that the
study drug aims to treat (in this case HFpEF) and the patients should
have a medium–high risk profile in order to allow the observation
of a potential treatment effect on an absolute scale (i.e. absolute
risk reduction). If the population has a very low level of risk or
does not have the disease (as in the case of the Eastern European .
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. patients in TOPCAT), the treatment effect will not be apparent as
there is little risk to be reduced.23 Moreover, future HFpEF trials
should apply a series of prespecified ‘rules’ (e.g. echocardiographic
parameters, cardiac collagen markers, NP levels, drug compliance,
potassium levels and renal function, and monitoring of events) in
order to help enrol patients who have the disease, who adhere to
treatment, and who have more opportunity to respond to therapy
(and suffer less harmful effects) as the trial may be adapted in order
to select patients who are likely to benefit more from treatment.
However, unless this protocol is prespecified before the trial is initi-
ated, we are likely to lose more opportunities for the development
of ‘personalized treatments’.
Populations at risk
Populations at risk for HF but without overt HF have a lower
baseline risk for major cardiovascular events in comparison with
HF populations.66 Hence, the risk reduction in an absolute scale
will necessarily be lower (as TOPCAT clearly demonstrated by
enrolling low-risk Eastern European populations in which event
rates overlapped those of the age-matched general population36)
and, in this case, patients likely to benefit from MRA therapy must
be carefully selected (‘NNT for benefit’ vs. ‘NNT for harm’).40
For this purpose, attention should focus on prespecified ‘response
predictors’ (as stated above). This approach will possibly avoid
overtreatment in lower-risk populations and select patients who
are more prone to respond (Table 3 and Figure 2).
Acutely decompensated heart failure
Preliminary data suggest that MRAs are safe in ADHF, but do not
point towards potential efficacy. However, improvement in patient
population selection and the formulation of the study drug should
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be tested before the administration of MRAs is concluded to be
futile (Table 3).
Ongoing trials in patients at risk
of developing heart failure
HOMAGE
The HOMAGE (Heart OMics in AGEing) project aims to validate
specific biomarkers of ageing, fibrosis, cardio-myocyte damage and
inflammation that allow the stratification of HF patients in order to
support the proposition of therapy tailored according to altered
signalling pathways (i.e. patients’ biomarker profiles). Hence the
project will use an innovative ‘omic-based’ approach that enables
the simultaneous investigation of a huge amount of transcripts,
proteins andmetabolites to set the basis for newways of preventing
HF.67 This might also allow for the repositioning of MRA therapy
as preventive treatment in at-risk patients with co-morbidities in
whom the signalling pathways cited above are known to be altered
(e.g. patients with obesity and/or chronic kidney disease). To this
purpose, a sub-study of HOMAGE will randomize patients at risk
for HF to spironolactone or ‘usual care’ in order to identify those
who are likely to respond based on prespecified cardiac collagen
marker levels (NCT02556450).
ALCHEMIST
The ALCHEMIST trial is designed to establish the effects of
spironolactone vs. placebo on major cardiovascular events in
chronic haemodialysis patients (NCT01848639).
Conclusions
In the absence of formal contraindications and until further RCTs
targeting specific subpopulations have been conducted, MRAs
should be provided to the great majority of HFrEF patients.
Spironolactone should be considered for use in symptomatic
HFpEF patients with elevated NP levels. Further trials should tar-
get HFrEF patients using the exclusion criteria applied in landmark
trials (e.g. severe renal impairment), select more homogeneous
HFpEF populations (e.g. with elevated BNP and structural abnor-
malities on echocardiography), and determine which patients are
more likely to benefit from MRAs (e.g. according to prespecified
biomarkers).
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